Overview

Bruxism Xeomin® Intervention Trial

Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether severe masticatory muscle spasms during sleep (e.g. teeth clenching and grinding, known as "bruxism" in technical jargon) demonstrably decrease after application of botulinum toxin type A (Xeomin®). Xeomin® has so far been used to relieve spasms of other muscles and is an approved drug in Switzerland. This study is now intended to test the suitability of this drug for relaxation of the masseter muscle.
Phase:
Phase 4
Details
Lead Sponsor:
Dominik Ettlin
Collaborator:
Merz Pharmaceuticals
Treatments:
incobotulinumtoxinA